Alector to Participate in the TD Cowen 46th Annual Health Care Conference
Rhea-AI Summary
Alector (Nasdaq: ALEC) said management will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 3:10 PM ET. A live webcast will be available on the company’s Investors “Events & Presentations” page, with a replay accessible for 90 days.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Momentum scanner flagged two biotech peers (ANNX, LCTX) moving up, but sector momentum is marked as stock-specific (false for sector move) and target direction is not defined, suggesting this conference update is being treated idiosyncratically.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 12 | Executive appointment | Neutral | -4.7% | Neil Berkley named permanent CFO and continues as Chief Business Officer. |
| Dec 01 | Conference participation | Neutral | -7.3% | Management participation in Bank of America CNS Therapeutics Conference. |
| Nov 06 | Quarterly earnings | Neutral | +3.6% | Q3 2025 results, cash runway into 2027, ABC programs and trial updates. |
| Oct 21 | Phase 3 topline data | Negative | -3.0% | Latozinemab Phase 3 failed clinical endpoint; workforce reduction and portfolio shift. |
| Sep 16 | R&D event | Positive | -6.8% | Virtual R&D event on PGRN franchise and ABC programs across neuro indications. |
Neutral or routine news (management changes, conferences, R&D events) has often coincided with negative next-day moves, while clearly clinical or earnings-related updates have shown more mixed, sometimes positive, reactions.
Over the last few months, Alector’s news flow has included management changes, conference participation, earnings, and major clinical updates. A Dec 10, 2025 CFO appointment and multiple conference/event announcements were followed by negative price reactions. By contrast, Q3 2025 financials and business update on Nov 6, 2025 saw a positive move despite reporting a net loss and a discontinued program. The October 2025 Phase 3 failure produced a modest decline. Today’s conference participation fits into a pattern of frequent investor‑facing communications alongside ongoing pipeline development and restructuring.
Market Pulse Summary
This announcement describes Alector’s participation in the TD Cowen health care conference on March 3, 2026, offering investors a webcast and 90-day replay to hear management’s corporate update. In the past six months, the company has reported a major Phase 3 setback, workforce reductions, and a cash runway into 2027, alongside advancing ABC-platform programs. Investors may focus on how this presentation contextualizes pipeline priorities, restructuring progress, and financial positioning relative to those prior disclosures.
AI-generated analysis. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in a corporate presentation at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 3:10 pm ET.
A live webcast of the corporate presentation will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. A replay will be available on the Alector website for 90 days following the event.
About Alector
Alector is a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of programs that aim to remove toxic proteins, replace missing proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector’s product candidates seek to treat a range of indications, such as Alzheimer’s disease, Parkinson's disease, and frontotemporal dementia. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being selectively applied to its preclinical and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit www.alector.com.
Alector Contacts:
Argot Partners (media)
David Rosen
(212) 600-1494
alector@argotpartners.com
Argot Partners (investors)
Laura Perry
(212) 600-1902
alector@argotpartners.com
FAQ
When will Alector (ALEC) present at the TD Cowen 46th Annual Health Care Conference?
How can investors watch the Alector (ALEC) presentation on March 3, 2026?
Will Alector (ALEC) make a replay of the TD Cowen presentation available?
What topics will Alector (ALEC) management likely cover at the March 3, 2026 presentation?
Where exactly is the Alector (ALEC) webcast hosted for the TD Cowen conference?
How long will the Alector (ALEC) presentation replay remain accessible after the TD Cowen event?
